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on CD14+ PBMCs under the stimulation of HBeAg with or
without anti-HBe antibody by ﬂow cytometry.
Results: Both in CHB patients and healthy people, TLR-2
decreased signiﬁcantly (t scores were 4.948 and 3.245, both
P values were below 0.05) and B7-H1 increased (t scores
were 3.612 and 2.341, both P values were below 0.05)
and IFN-g decreased signiﬁcantly (CHB group, t = 2.184 and
P = 0.050, healthy control group, t = 2.800 and P = 0.030)
after incubation with HBeAg. TLR-2 also decreased under
the stimulation of HBeAg with anti-HBe antibody, but there
was no statistical difference compared with incubation with
HBeAg alone (P > 0.05).
Conclusions HBeAg could increase the negative
costimulatory molecule B7-H1, inhibit TLR-2 and IFN-g,
these lead to the reduced capacity of speciﬁc CTLs in viral
clearance.
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Objective: To analyze HBsAg titre variational tendency in
patients with chronic hepatitis B (CHB), HBV-related liver
cirrhosis (LC) and hepatocellular carcinoma (HCC), and the
correlation with HBV DNA in each disease.
Methods: HBsAg titre and HBV DNA were measured
in 47 CHB, 72 LC and 54 HCC patients used Abbott
chemiluminescence and a real-time PCR respectively.
Results: HBsAg titre level in serum decreased from
CHB [2361.10 (975.69 5427.96) IU/mL] to LC [1001.64
(318.72 1819.99) IU/mL] and HCC [594.35 (133.75 1337.00)
IU/mL], and there were statistically signiﬁcant different
(c2 = 24.394, P < 0.001). Moreover, HBsAg titre was
signiﬁcantly higher in CHB than LC (Z = 3.754, P < 0.001),
CHB had signiﬁcantly higher HBsAg titre than HCC
(Z = 4.630, P < 0.001), however, LC and HCC had no
statistically signiﬁcant different (Z = 1.720, P = 0.085).
In HBeAg positive patients, HBsAg titre decreased from
CHB [3259.83 (1710.60 7547.85) IU/mL] to LC [1077.30
(374.39 2553.59) IU/mL] and HCC [789.72 (162.97 1470.95)
IU/mL], and there were signiﬁcant different (c2 = 15.643,
P < 0.0001). In HBeAg negative patients, the decline
of HBsAg titre among CHB [1669.00 (240.78 2920.97)
IU/mL] to LC [1001.64 (115.91 1609.59) IU/mL] and HCC
[582.05 (133.75 1209.07) IU/mL] had signiﬁcant different
(c2 = 6.423, P = 0.04). Correlation between HBsAg titre
and HBV DNA was found in CHB (r = 0.297, P = 0.043),
LC (r = 0.346, P = 0.003) and HCC (r = 0.452, P = 0.001),
respectivly.
Conclusion: HBsAg titre level in serum decreased
progressively from CHB to LC and HCC group. There were
positive correlations between HBsAg titre and HBV DNA level
in CHB, LC and HCC.
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Objectives: Investigate the efﬁcacy of a Chinese herbal
compound prescription (CHCP) for 32 HBeAg positive chronic
hepatitis patients’ two year anti-HBV infection treatments.
Methods: The main ingredients of the CHCP have Chaihu,
Huangqi and Diding. The main prescription consists of 11
herbal ingredients, which was used for all patients. The
sub-prescription consists of 2 4 herbal ingredients, which
was used for patients based on their different symptoms.
The patients took the decocted CHCP two times each day
at least half one hour after meals.
Results: Of 32 CHCP-treated patients, ten (31.2%) have
obtained HBeAg seroconversion, ALT normalization, and with
HBV DNA <1000copies/mL (lower limit of detection). These
patients’ baseline average characters were Age = 25.8 years
old, ALT = 197.74U/L, HBV DNA = 5.71e7 copies/ml, and
HBeAg = 551.25S/CO. The average time to achieve HBV DNA
<1000 copies/ml was 72 weeks. The other 22 CHCP-treated
patients’ baseline average characters were Age = 35.5 years
old, ALT = 148.75U/L, HBV DNA = 4.26e7copies/ml, and
HBeAg = 796.99S/CO. For all CHCP-treated patients, neither
demonstrated substitutions associated with NTCB resistance
or the common adverse events and renal events.
Conclusion: Two years CHCP anti-HBV Infection therapy
is quite effective for the HBeAg positive younger patients
whose baseline ALT >200U/L, HBeAg <500S/CO, and HBV DNA
<1e8copies/ml. The CHCP is safe for long-term’s anti-HBV
infection personalized therapy.
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Background: HBeAg is important for establishment of
persistent infection. The aim of this study was to detect
the regulation of TLRs, PD-1/PD-L1 expression and cytokine
secretion on PBMCs by HBeAg.
Methods: Anti-HBe serum was collected from CHB with
anti-HBe positive; PBMCs were isolated from healthy
persons; Cytokines secretion were detected by CBA; RT-
PCR examined TLR2, TLR4mRNA.
Result: CD14+ PBMCs of TLR2 was signiﬁcantly reduced
in HBeAg-group compared to control (p = 0.003). TLR4
expression on CD3+ cells in HBeAg-group was signiﬁcantly
decreased, but expressions of PD-1 and PD-L1 were
signiﬁcantly up-regulation; However, when HBeAg was
reactivity against by Anti-HBe, the expression of TLR4, PD-1,
PD-L1 on CD14+ cells and CD3+ cells were improved. At the
same time, cytokines expression were detected, HBeAg was
able to signiﬁcantly down-regulate IL-2, IL-17 and IFN-g,
but up-regulate IL-10 (P< 0.005). RT-PCR illustrated that
HBeAg was able to signiﬁcantly down-regulate TLR2 mRNA
on PBMCs (p = 0.001), while HBeAg was blocked with anti-
HBe, the expression TLR2 mRNA was improved (p < 0.05).
Conclusion: HBeAg was able to signiﬁcantly suppress TLR2
and TLR4 expression and mRNA on CD14+ PBMCs and
PD-L1/PD-1 expressions on PBMCs, yet HBeAg blocked
with anti-HBe could improve the expression of mRNA and
decrease the expression of PD-L1 and PD-1; HBeAg was able
to signiﬁcantly down-regulate proinﬂammatory cytokines.
These results promoted that HBeAg may be through the
way suppressed expression of inﬂammatory factors genes
induced by TLRs signal pathway and regulated secretion
of cytokines to establish persistent infection in chronic
hepatitis B patients.
